Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 13/20 | 0.56 |
| ▸ | KCNK18 | Q7Z418 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.46 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552917 | 0.81 | TAS2R14 (0.64) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL21749236 | 0.78 | TAS2R14 (0.79) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL25787885 | 0.76 | TAS2R14 (0.67) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL25788464 | 0.76 | TAS2R14 (0.67) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL20552361 | 0.75 | KCNK18 (0.57) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL20553148 | 0.75 | GPR35 (0.66) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL20551742 | 0.75 | TAS2R14 (0.62) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL25786548 | 0.73 | TSHR (0.44) | POLBMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL20552766 | 0.73 | KCNK18 (0.67) | TAS2R14KCNK18MEN1KMT2AALDH1A1 | |
| SCHEMBL20552499 | 0.73 | TAS2R14 (0.59) | TAS2R14KCNK18MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | TAS2R14 4740/4885KCNK18 4529/4885POLB 2074/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | TAS2R14 4740/4885KCNK18 4529/4885POLB 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.